Primmune
  • About
  • Science
  • Therapeutic Focus
  • Team
  • Publications
  • News
  • Contact
Select Page

Primmune Therapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

Mar 10, 2022 | Press Releases

SAN DIEGO, March 10, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...

Primmune Therapeutics to Participate in the 12th Annual Biocom Global Life Science Partnering Conference

Feb 24, 2022 | Press Releases

SAN DIEGO, February 24, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...

Primmune Therapeutics Presents Interim Analysis of Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)

Feb 14, 2022 | Press Releases

— Oral administration of PRTX007 exhibits favorable safety profile, rapid conversion to TLR7 agonist PRX034, and activation of the innate immune system, without an increase in proinflammatory factors — SAN DIEGO, February 14, 2022 – Primmune Therapeutics, a biotech...

Primmune Therapeutics to Present Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)

Feb 7, 2022 | Press Releases

SAN DIEGO, February 7, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat viral diseases and cancers, today announced that they will present data related to PRTX007, a novel, orally administered, small molecule...

Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing

Nov 4, 2021 | Press Releases

SAN DIEGO, November 4, 2021 – Primmune Therapeutics today announced that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million. These funds will be used to...

Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™

Nov 2, 2021 | Press Releases

SAN DIEGO, November 2, 2021 – Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including...
« Older Entries
Next Entries »
© Primmune Therapeutics | Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn

We use cookies to improve your experience on the Primmune website. By continuing to use our site, you agree to our use of cookies.
Learn More